Epidemiological and therapeutic profile in atopic dermatitis according to the involvement on special locations. Spanish atopic dermatitis registry (BIOBADATOP)
Background. The development of new therapies for atopic dermatitis (AD) has represented a qualitative leap in disease control. However, involvement of special locations (SL) may pose a challenge, given its association with a high impact on quality of life that is not always related to objective exte...
| Autores: | , , , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Recursos: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:dnet:idus________::710e2f1c1bb92295525c15a0db144abc |
| Acesso em linha: | https://hdl.handle.net/11441/186212 https://doi.org/10.1016/j.ad.2026.104677 |
| Access Level: | acceso abierto |
| Palavra-chave: | Atopic dermatitis Special locations Prospective cohort Face Genitals Hands Dermatitis atópica Localizaciones especiales Cohorte prospectiva Cara Genitales Manos |
| Resumo: | Background. The development of new therapies for atopic dermatitis (AD) has represented a qualitative leap in disease control. However, involvement of special locations (SL) may pose a challenge, given its association with a high impact on quality of life that is not always related to objective extension. Material and methods. We used the BIOBADATOP registry (Spanish AD Registry). We conducted a descriptive analysis of the epidemiology of SL involvement, as well as its therapeutic and prognostic implications. Three areas were defined as SL: the face, genitals, and hands. Patients were grouped according to the absence of involvement, involvement of one SL, or involvement of > 2 SLs. Results. Of the 616 patients included, 70% presented facial involvement, 46.6% hand involvement, and 28.2% genital involvement. Among adults (82.1%; N = 506), 23.7% presented involvement of 1 SL and 52.8% involvement of > 2SLs. Greater SL involvement was associated with a higher number of previous systemic treatments and higher baseline EASI and POEM scores, among other findings. In the pediatric group (17.9%; N = 110), 30% presented involvement of 1 SL and 45.5% involvement of > 2 SLs. A greater number of previous treatments was also recorded compared with patients without SL involvement. Conclusions. Involvement of SLs tends to be associated with greater baseline severity and a higher number of previous systemic treatments, a circumstance that should be taken into consideration in the management of these patients. |
|---|